IP Library › Granted Patent US 9,526,736
Granted Patent B2
US 9,526,736 · App. 14/597,764 · Granted Dec 27, 2016

Transdermal therapeutic system comprising norelgestromin for contraception and hormone replacement

Inventors: Frank Theobald (Wehr, DE); René Eifler (Koblenz, DE)
Assignee: LTS Lohmann Therapie-Systeme AG
A61K31/57A61K9/7069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,526,736
App. No.
14/597,764
Granted
Dec 27, 2016
Kind
B2
Abstract

The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy.

Claims (56)

1. A transdermal therapeutic system for administration of norelgestromin and ethinyl estradiol, the transdermal therapeutic system comprising:

a norelgestromin and ethinyl estradiol-impermeable backing layer;

at least one norelgestromin and ethinyl estradiol-containing matrix layer; and

optionally a detachable protective layer;

wherein the matrix layer comprises:

a) a therapeutically effective dose of norelgestromin and ethinyl estradiol;

b) one or more silicone polymers; and

c) a substance for solubilizing the norelgestromin and ethinyl estradiol in the one or more silicone polymers;

wherein the substance is diethylene glycol monoethyl ether; and

wherein the norelgestromin and ethinyl estradiol are solubilized in the one or more silicone polymers.

2. The transdermal therapeutic system as claimed in claim 1 ;

wherein an application area of said system is smaller than 20 cm 2 .

3. The transdermal therapeutic system as claimed in claim 1 , further comprising:

one or more fatty acid salts.

4. The transdermal therapeutic system as claimed in claim 1 , further comprising:

a polymer or combinations of such polymers selected from the group consisting of ethyl-, methyl cellulose, polyvinylpyrrolidone, and lactose.

5. The transdermal therapeutic system as claimed in claim 1 , further comprising:

one or more substances or combinations thereof selected from the group consisting of silicone oil, glycerol esters of hydrogenated resin acids, hydroabietic alcohol resin esters, hydroabietic acid resin esters, hydrogenated methyl esters of terpentine resins, esters of partially hydrogenated terpentine resins and esters of terpentine resins.

6. The transdermal therapeutic system as claimed in claim 1 , further comprising:

a substance or combinations of such substances selected from the group consisting of tragacanth, bentonite, lactose, and colloidal silicon dioxide.

7. The transdermal therapeutic system as claimed in claim 1 , further comprising:

one or more antioxidants.

8. The transdermal therapeutic system as claimed in claim 1 ;

wherein the transdermal therapeutic system is transparent or translucent.

9. The transdermal therapeutic system as claimed in claim 1 , further comprising:

a nonwoven supporting layer.

10. The transdermal therapeutic system as claimed in claim 9 ;

wherein the norelgestromin and ethinyl estradiol are dissolved or suspended in diethylene glycol monoethyl ether, and optionally the norelgestromin and ethinyl estradiol are applied to the nonwoven.

11. The transdermal therapeutic system as claimed in claim 9 ;

wherein the nonwoven supporting layer comprises polyethylene terephthalate, regenerated cellulose, cellulose nitrate, or polyethylene.

12. The transdermal therapeutic system as claimed in Claim 1 ;

wherein the transdermal therapeutic system comprises a plurality of layers which differ in their composition and/or norelgestromin and ethinyl estradiol content.

13. A method of providing hormonal contraception to a patient in need thereof, the method comprising:

administering the transdermal therapeutic system of claim 1 to the patient.

14. A method of providing hormone replacement to a patient in need thereof, the method comprising:

administering the transdermal therapeutic system of claim 1 to the patient.

15. The transdermal therapeutic system as claimed in claim 4 ;

wherein the one or more fatty acid salts include sodium laurate.

16. The transdermal therapeutic system as claimed in claim 1 ;

wherein the substance includes a pressure-sensitive silicone adhesive.

17. A transdermal therapeutic system for administration of norelgestromin and ethinyl estradiol, the transdermal therapeutic system comprising:

a norelgestromin and ethinyl estradiol-impermeable backing layer;

at least one norelgestromin and ethinyl estradiol-containing matrix layer; and

optionally a detachable protective layer;

wherein the matrix layer comprises:

a) a therapeutically effective dose of norelgestromin and ethinyl estradiol;

b) a pressure-sensitive silicon adhesive;

c) diethylene glycol monoethyl ether;

d) DL-α-tocopherol;

e) polyvinylpyrrolidone; and

f) sodium laurate;

wherein the norelgestromin and ethinyl estradiol are solubilized in the pressure-sensitive silicon adhesive.

18. The transdermal therapeutic system as claimed in claim 17 ;

wherein an application area of said system is smaller than 20 cm 2 .

19. The transdermal therapeutic system as claimed in claim 17 , further comprising:

DL-α-tocopherol, polyvinylpyrrolidone and sodium laurate.

Priority Claims (1)
DE 10 2006 050 558 · Oct 26, 2006 · national
Continuity (2)
Continuation 12446887
Related Publication 20150231154A1 · Aug 20, 2015